Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27228311 | 0.95 | CHRM2 (0.53) | CHRM2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL31016709 | 0.87 | CHRM2 (0.44) | CHRM2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL27228300 | 0.87 | CHRM2 (0.44) | CHRM2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL31016691 | 0.84 | CYP2D6 (0.46) | CHRM2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL27228323 | 0.84 | CYP2C9 (0.53) | CYP2D6CYP3A4TSHRCYP2C19CYP2C9 | |
| SCHEMBL27228352 | 0.84 | CYP2D6 (0.46) | CHRM2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL31016665 | 0.84 | CYP2C9 (0.53) | CYP2D6CYP3A4TSHRCYP2C19CYP2C9 | |
| SCHEMBL27228582 | 0.82 | CYP2D6 (0.49) | CHRM2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL31016653 | 0.82 | GPR6 (0.42) | CHRM2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL31016701 | 0.82 | KDM4E (0.42) | CHRM2CYP2D6CYP3A4TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-05-30 | — | — | US | claimed |
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | SIGMAR1, OPRD1, TMEM97 | CHRM2 205/4885CYP2D6 438/4885CYP3A4 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.